HYDERABAD: Natco Pharma Ltd has launched a generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination in Nepal.
It will market the product under the VELPANAT brand name and priced at an MRP of Rs.25,000 equivalent for a bottle of 28 tablets in Nepal.
The launch is under a non-exclusive licensing agreement that Natco has with Gilead Sciences Inc. to manufacture and sell generic versions of the latter’s chronic hepatitis C medicines in 101 developing countries. The fixed dose combination is sold by Gilead Sciences Inc. under the Epclusa brand name. Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection, a Natco Pharma release on Monday said.
Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin, the release said.
EOM
